Tag Archives: Geulah Livshits

Logicbio Therapeutics Inc (LOGC) Gets a Buy Rating from Chardan Capital

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Logicbio Therapeutics Inc (LOGC – Research Report) today and set a price target of $20. The company’s shares closed last Monday at $8.01, close to its 52-week low of $6.70.

Chardan Capital Keeps a Buy Rating on Replimune Group Inc (REPL)

In a report released yesterday, Geulah Livshits from Chardan Capital reiterated a Buy rating on Replimune Group Inc (REPL – Research Report), with a price target of $28. The company’s shares closed last Monday at $10.05, close to its 52-week

Chardan Capital Reiterates a Hold Rating on Vascular Biogenics (VBLT)

In a report released today, Geulah Livshits from Chardan Capital reiterated a Hold rating on Vascular Biogenics (VBLT – Research Report), with a price target of $3. The company’s shares closed last Monday at $1.17. According to TipRanks.com, Livshits is

Chardan Capital Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Intellia Therapeutics (NTLA – Research Report), with a price target of $57.50. The company’s shares opened today at $19. Livshits wrote: “We believe Intellia is

Analysts Offer Insights on Healthcare Companies: Logicbio Therapeutics Inc (NASDAQ: LOGC) and Lexicon Pharmaceuticals (NASDAQ: LXRX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Logicbio Therapeutics Inc (LOGC – Research Report) and Lexicon Pharmaceuticals (LXRX – Research Report). Logicbio Therapeutics Inc (LOGC) Chardan Capital analyst Geulah Livshits reiterated a

Editas Medicine Inc (EDIT) Receives a Buy from Chardan Capital

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Editas Medicine Inc (EDIT – Research Report) today and set a price target of $55. The company’s shares opened today at $26.11. Livshits wrote: “We anticipate better visibility around potential